Paroxetine

We are open as normal during COVID-19 pandemic. Order online, same day shipping out.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 584260

CAS#: 61869-08-7

Description: Paroxetine is a serotonin uptake inhibitor that is effective in the treatment of depression.


Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-07-15. Prices are subject to change without notice.

Paroxetine is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 584260
Name: Paroxetine
CAS#: 61869-08-7
Chemical Formula: C19H20FNO3
Exact Mass: 329.1427
Molecular Weight: 329.3714
Elemental Analysis: C, 69.29; H, 6.12; F, 5.77; N, 4.25; O, 14.57


Synonym: Paroxetine

IUPAC/Chemical Name: Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, (3S,4R)-

InChi Key: AHOUBRCZNHFOSL-YOEHRIQHSA-N

InChi Code: InChI=1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1

SMILES Code: FC1=CC=C([C@H]2[C@H](COC3=CC=C(OCO4)C4=C3)CNCC2)C=C1


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


References

1: Sanchez C, Reines EH, Montgomery SA. A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike? Int Clin Psychopharmacol. 2014 Jul;29(4):185-96. doi: 10.1097/YIC.0000000000000023. Review. PubMed PMID: 24424469; PubMed Central PMCID: PMC4047306.

2: Germann D, Ma G, Han F, Tikhomirova A. Paroxetine hydrochloride. Profiles Drug Subst Excip Relat Methodol. 2013;38:367-406. doi: 10.1016/B978-0-12-407691-4.00008-3. Review. PubMed PMID: 23668408.

3: Tomita T, Yasui-Furukori N, Nakagami T, Tsuchimine S, Ishioka M, Kaneda A, Nakamura K, Kaneko S. Therapeutic reference range for plasma concentrations of paroxetine in patients with major depressive disorders. Ther Drug Monit. 2014 Aug;36(4):480-5. doi: 10.1097/FTD.0000000000000036. PubMed PMID: 25014076.

4: Ravindran AV, Cameron C, Bhatla R, Ravindran LN, da Silva TL. Paroxetine in the treatment of dysthymic disorder without co-morbidities: A double-blind, placebo-controlled, flexible-dose study. Asian J Psychiatr. 2013 Apr;6(2):157-61. doi: 10.1016/j.ajp.2012.10.004. Epub 2012 Nov 17. PubMed PMID: 23466114.

5: Zarei M, Sabetkasaei M, Moini Zanjani T. Paroxetine attenuates the development and existing pain in a rat model of neurophatic pain. Iran Biomed J. 2014;18(2):94-100. PubMed PMID: 24518550; PubMed Central PMCID: PMC3933918.

6: Olgiati P, Serretti A. Persistent benefits of slow titration of paroxetine in a six-month follow-up. Hum Psychopharmacol. 2015 Sep;30(5):329-33. doi: 10.1002/hup.2478. Epub 2015 Apr 21. PubMed PMID: 25900268.

7: Schutters SI, van Megen HJ, Van Veen JF, Schruers KR, Westenberg HG. Paroxetine augmentation in patients with generalised social anxiety disorder, non-responsive to mirtazapine or placebo. Hum Psychopharmacol. 2011 Jan;26(1):72-6. doi: 10.1002/hup.1165. Epub 2011 Feb 9. PubMed PMID: 23055414.

8: Tomita T, Yasui-Furukori N, Nakagami T, Tsuchimine S, Ishioka M, Kaneda A, Sugawara N, Kaneko S. The influence of 5-HTTLPR genotype on the association between the plasma concentration and therapeutic effect of paroxetine in patients with major depressive disorder. PLoS One. 2014 May 23;9(5):e98099. doi: 10.1371/journal.pone.0098099. eCollection 2014. PubMed PMID: 24858363; PubMed Central PMCID: PMC4032230.

9: Kaspersen H, Agmo A. Paroxetine-induced reduction of sexual incentive motivation in female rats is not modified by 5-HT1B or 5-HT2C antagonists. Psychopharmacology (Berl). 2012 Mar;220(2):269-80. doi: 10.1007/s00213-011-2475-1. Epub 2011 Sep 10. PubMed PMID: 21909633.

10: El-Nabarawi MA, Bendas ER, El Rehem RT, Abary MY. Transdermal drug delivery of paroxetine through lipid-vesicular formulation to augment its bioavailability. Int J Pharm. 2013 Feb 25;443(1-2):307-17. doi: 10.1016/j.ijpharm.2013.01.016. Epub 2013 Jan 18. PubMed PMID: 23337629.

11: Kim JR, Woo HI, Chun MR, Lim SW, Kim HD, Na HS, Chung MW, Myung W, Lee SY, Kim DK. Exposure-outcome analysis in depressed patients treated with paroxetine using population pharmacokinetics. Drug Des Devel Ther. 2015 Sep 16;9:5247-54. doi: 10.2147/DDDT.S84718. eCollection 2015. PubMed PMID: 26396498; PubMed Central PMCID: PMC4577253.

12: Amodeo L, Castelli L, Leombruni P, Cipriani D, Biancofiore A, Torta R. Slow versus standard up-titration of paroxetine for the treatment of depression in cancer patients: a pilot study. Support Care Cancer. 2012 Feb;20(2):375-84. doi: 10.1007/s00520-011-1118-8. Epub 2011 Mar 15. PubMed PMID: 21404089.

13: Polak AR, Witteveen AB, Visser RS, Opmeer BC, Vulink N, Figee M, Denys D, Olff M. Comparison of the effectiveness of trauma-focused cognitive behavioral therapy and paroxetine treatment in PTSD patients: design of a randomized controlled trial. BMC Psychiatry. 2012 Oct 9;12:166. doi: 10.1186/1471-244X-12-166. PubMed PMID: 23046608; PubMed Central PMCID: PMC3539952.

14: Li F, Zhang M, Xu D, Liu C, Zhong ZY, Jia LL, Hu MY, Yang Y, Liu L, Liu XD. Co-administration of paroxetine and pravastatin causes deregulation of glucose homeostasis in diabetic rats via enhanced paroxetine exposure. Acta Pharmacol Sin. 2014 Jun;35(6):792-805. doi: 10.1038/aps.2014.24. PubMed PMID: 24902787; PubMed Central PMCID: PMC4086381.

15: Inoue H, Harada T, Eto S, Nakashima K, Ibusuki T, Kosha K, Date Y, Sanematsu E, Shinohara Y, Takahashi K, Yoshimura R, Nakamura J, Kojima E, Tsuruta Y. Determination of paroxetine in serum treated with simple pretreatment by pre-column high-performance liquid chromatography using 4-(5,6-dimethoxy-2-phthalimidinyl)-2-methoxyphenylsulfonyl chloride as a fluorescent labeling reagent. Biomed Chromatogr. 2013 Jun;27(6):688-90. doi: 10.1002/bmc.2859. Epub 2013 Jan 14. PubMed PMID: 23319205.

16: Paroxetine (Brisdelle) for hot flashes. Med Lett Drugs Ther. 2013 Oct 28;55(1428):85-6. PubMed PMID: 24165707.

17: Gibiino S, Serretti A. Paroxetine for the treatment of depression: a critical update. Expert Opin Pharmacother. 2012 Feb;13(3):421-31. doi: 10.1517/14656566.2012.652085. Epub 2012 Jan 21. Review. PubMed PMID: 22263916.

18: Ball WA, Snavely DB, Hargreaves RJ, Szegedi A, Lines C, Reines SA. Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder. Hum Psychopharmacol. 2014 Nov;29(6):568-77. doi: 10.1002/hup.2444. Epub 2014 Oct 20. PubMed PMID: 25330122.

19: Ruiz-Garcia A, Giri N, LaBadie RR, Ni G, Boutros T, Richie N, Kocinsky HS, Checchio TM, Bello CL. A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers. J Clin Pharmacol. 2014 May;54(5):555-62. doi: 10.1002/jcph.243. Epub 2013 Dec 17. PubMed PMID: 24293056.

20: do Monte ZS, Ramos CS. Development and validation of a method for the analysis of paroxetine HCl by circular dichroism. Chirality. 2013 Apr;25(4):211-4. doi: 10.1002/chir.22122. PubMed PMID: 23532996.